Burosumab Therapy in Children with X-Linked HypophosphatemiaThomas O. Carpenter, Anthony A. Portale, Meng Mao et al.|New England Journal of Medicine|2018Cited by 479
Burosumab versus conventional therapy in children with X-linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trialErik A. Imel, Anthony A. Portale, Francis H. Glorieux et al.|The Lancet|2019Cited by 375
Rickets severity predicts clinical outcomes in children with X-linked hypophosphatemia: Utility of the radiographic Rickets Severity ScoreTom D. Thacher, Thomas O. Carpenter, John Μ. Pettifor et al.|Bone|2019Cited by 75
Growth Curves for Children with X-linked HypophosphatemiaMeng Mao, Alan D. Rogol, Thomas O. Carpenter et al.|The Journal of Clinical Endocrinology & Metabolism|2020Cited by 42